MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
Basic Information
ID: ALA3875190
Journal: Bioorg Med Chem Lett
Title: MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
Authors: Haidle AM, Childers KK, Zabierek AA, Katz JD, Jewell JP, Hou Y, Altman MD, Szewczak A, Chen D, Harsch A, Hayashi M, Warren L, Hutton M, Nuthall H, Stanton MG, Davies IW, Munoz B, Northrup A.
Abstract: Attempts to optimize pharmacokinetic properties in a promising series of pyrrolopyrimidinone MARK inhibitors for the treatment of Alzheimer's disease are described. A focus on physical properties and ligand efficiency while prosecuting this series afforded key tool compounds that revealed a large discrepancy in the rat in vitro-in vivo DMPK (Drug Metabolism/Pharmacokinetics) correlation. These differences prompted an in vivo rat disposition study employing a radiolabeled representative of the series, and the results from this experiment justified the termination of any further optimization efforts.
CiteXplore: 27894874
DOI: 10.1016/j.bmcl.2016.08.066
Patent ID: ┄